JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Skip to the beginning of the images gallery

Mfg Part Number

Ab05114-10.3

Vector Labs Ab05114-10.3 Anti-LCMV surface glycoprotein [M28], Human IgG1, Fc Silent™, kappa (100 μg)

VECTOR LABS

Be the first to review this product

Quick Overview

The original antibody was generated by introducing two mutations (S32R and R55 insertion) into the sequence of the parent clone 18.5C (an isolate from a human survivor of Lassa fever).

$570.70

Order will ship within 1-3 business days

Description

Product Class: Purified
Clone ID: M28
Heavy Chain Modification: Fc Silent™
Synonyms: LCMV surface GP; lineage I Lassa fever virus; lineage I LASV; LASV; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2; 18.5C-M28
Amount: 100 μg
Application Codes Clone: ELISA; Neutralization; in vitro; in vivo; CryoEM
Shipping Temperature: Wet Ice
Origin Pub PMID: 36990092
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for the LCMV surface glycoprotein. It binds to a pre-fusion epitope of the LCMV GP complex.
Application Notes: The original antibody (human IgG1) was generated and confirmed to specifically recognize the target via ELISA. A Fab version of it was generated and tested for neutralization. This antibody demonstrated potent in vitro neutralization (IC₅₀ ≈ 0.51 μg/mL) and both prophylactic and therapeutic efficacy in a murine chronic LCMV model, with complete viral clearance and protection from weight loss. Furthermore, this antibody enabled high-resolution cryoEM of the LCMV GP trimer in both apo and Fab-bound states, defining a quaternary, pre-fusion-specific epitope (Moon-Walker et al., 2023; PMID: 36990092). In vitro, this antibody fully neutralized cell-free LCMV at 5 µg/mL and was used to demonstrate that ~50% of viral spread occurs via antibody-resistant, direct cell-to-cell nanotube transfer (Byford et al., 2024; PMID: 39578605).

Product Class:	Purified
Clone ID:	M28
Heavy Chain Modification:	Fc Silent™
Synonyms:	LCMV surface GP; lineage I Lassa fever virus; lineage I LASV; LASV; Pre-glycoprotein polyprotein GP complex; Pre-GP-C; Stable signal peptide; SSP; Glycoprotein G1; GP1; Glycoprotein G2; GP2; 18.5C-M28
Amount:	100 μg
Application Codes Clone:	ELISA; Neutralization; in vitro; in vivo; CryoEM
Shipping Temperature:	Wet Ice
Origin Pub PMID:	36990092
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for the LCMV surface glycoprotein. It binds to a pre-fusion epitope of the LCMV GP complex.
Application Notes:	The original antibody (human IgG1) was generated and confirmed to specifically recognize the target via ELISA. A Fab version of it was generated and tested for neutralization. This antibody demonstrated potent in vitro neutralization (IC₅₀ ≈ 0.51 μg/mL) and both prophylactic and therapeutic efficacy in a murine chronic LCMV model, with complete viral clearance and protection from weight loss. Furthermore, this antibody enabled high-resolution cryoEM of the LCMV GP trimer in both apo and Fab-bound states, defining a quaternary, pre-fusion-specific epitope (Moon-Walker et al., 2023; PMID: 36990092). In vitro, this antibody fully neutralized cell-free LCMV at 5 µg/mL and was used to demonstrate that ~50% of viral spread occurs via antibody-resistant, direct cell-to-cell nanotube transfer (Byford et al., 2024; PMID: 39578605).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews